STENT THROMBOSIS IN REAL WORLD REGISTRY PATIENTS
Introduction: Many risk factors for stent thrombosis (ST) have been identified, some modifiable and some not. Adequate patient, lesion, and stent selection; a good technical result; and effective treatment are critical in minimizing the risk of ST.In this observational clinical study we tried to elucidate the predictors of ST in real world percutaneous coronary intervention (PCI) patients.Material and methods: Patients who underwent percutaneous coronary interventions with stent implantation were included in a prospective study for 9 months. ST was defined according to Academic Research Consortium for definitive ST.Conditional logistic regression analysis was performed to determine independent predictors.Results: A total of 194 consecutive PCI patients were included in the study. The mean age was 59.37±11.04years. After 9 months, the total number of definitive stent thrombosis was 7 (3.6%).In the last model of the multivariate analysis two most powerful predictors of stent thrombosis emerged.In patients who had interrupted DAPT therapy, the risk for stent thrombosis was 4.6 times higher than in the rest of the PCI population and long lesions elevated the risk by 1.28 times (HR: 4.63, 95% CI: 2.64 to 17.63, p= 0.0007); (HR: 1.28, 95% CI: 1.14to 1.56, p= 0.0003), respectively. Conclusions: Stent thrombosis is a multifactorial disease. There is interaction of clinical, angiographic characteristics and also patient’s adherence to treatment. Risk factors identification obtains possibility to identify patients who would benefit from alternative therapy.
2. Holmes DR, Kereiakes DJ, Gard S et al. Stent Thrombosis. JACC. 2010; 56 (17):1357-65
3. Claessen BE, Henriques JPS, Jaffer PA et al. Stent thrombosis. A clinical perspective. JACC 2014;7 (10):1081-92
4. van Werkum JW, Heestermans AA, Zomer AC et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. Circ Cardiovasc Interv. 2009 Oct; 2(5):401-8.
5. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344–51.
6. Grines CL. Off-label use of drug-coated stents: putting it in perspective. J Am Coll Cardiol 2008; 51:615–7.
7. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug coated coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519–21.
8. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-coated stents. J Am Coll Cardiol 2005; 45:2088–92.
9. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-coated and bare metal stents: a collaborative network Meta analysis. Lancet 2007; 370:937–48.
10. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus and paclitaxel-coated coronary stents. N Engl J Med 2007; 356:998 –1008.
11. Pinto Slottow TL, Steinberg DH, Roy PK, et al. Observations and outcomes of definite and probable drug-coated stent thrombosis seen at a single hospital in a four-year period. Am J Cardiol 2008; 102:298 – 303.
12. Naidu SR, Krucoff MW, Rutledge DR, Mao WV et al. Contemporary incidence and predictors of stent thrombosis and other major cardiac adverse events in the year after Xience V implantation. JACC.2012;5(6):626 –35
13. Jensen LO, Maeng M, Kaltoft A et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol. 2007 Jul 31; 50(5):463-70.
14. Lagerqvist B, Carlsson J, Fröbert O et al. Stent thrombosis in Sweden: a report from the Swedish Coronary Angiography and Angioplasty Registry. Circ Cardiovasc Interv. 2009; 2(5):401-8.
15. Doostzadeh J, Clark LN, Bezenek S et al. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent. Coron Artery Dis. 2010; 21(1):46-56.